Incremental direct medical expenditures associated with anxiety disorders for the U.S. adult population: Evidence from the Medical Expenditure Panel Survey
Section snippets
Data source
Data was collected from Medical Expenditure Panel Survey (MEPS) public use data files. MEPS is a set of large-scale surveys of families, individuals, their medical providers and employers across the United States (Survey Background, 2009). Jointly sponsored by the Agency for Healthcare Research and Quality (AHRQ) and the National Center for Health Statistics (NCHS), MEPS has been conducted annually since 1996. It has three major components; the Household Component (HC), the Insurance Component
Results
From the total survey respondents in 2009–2010 (n = 66,148), 46,572 (weighted sum = 228,987,954) were adults with positive person weights and non-missing values on all of the independent variables, and were included in the final analysis.
In 2009–2010 MEPS survey, 8.74% (weighted sum = 20,337,553) of adults (95% CI: 8.32% to 9.17%) reported being diagnosed with an anxiety disorder(s). The remaining 91.26% were considered as anxiety-free population.
Discussion
This study used a nationally representative database along with a robust statistical analysis technique to provide the most comprehensive and recent estimates of direct medical costs of anxiety disorders among adults in the U.S. Our results showed that almost 9% of the ambulatory adult population of the U.S. in 2009–2010 were diagnosed with anxiety disorder(s). This estimate is lower than the 18.1% estimate for the 12-month prevalence of any anxiety disorder, reported by the National
Conclusion
In summary, the present study provides estimates of annual direct medical expenditures associated with anxiety disorders in the ambulatory adult population of the U.S. Our results confirmed that anxiety disorders impose a significant economic burden to society. This category of mental illnesses is associated with high overall healthcare cost, as well as higher cost for inpatient care, office-based visits, prescription medication, and emergency care. Our findings suggest that a significant
References (41)
- et al.
Economic costs of social phobia: a population-based study
Journal of Affective Disorders
(2009) - et al.
Incremental expenditure of treating hypertension in the United States
American Journal of Hypertension
(2006) - et al.
Economic costs of full-blown and subthreshold panic disorder
Journal of Affective Disorders
(2007) - et al.
Too much ado about two-part models and transformation? Comparing methods of modeling Medicare expenditures
Journal of Health Economics
(2004) - et al.
Practical considerations on the use of the Charlson comorbidity index with administrative data bases
Journal of Clinical Epidemiology
(1996) - et al.
Medical utilization across the anxiety disorders
Journal of Anxiety Disorders
(2008) - et al.
Service utilization and expenditures for the treatment of panic disorder
General Hospital Psychiatry
(1997) - et al.
The economic consequences of social phobia
Journal of Affective Disorders
(2002) - et al.
Medical utilisation and costs in panic disorder: a comparison with social phobia
Journal of Anxiety Disorders
(1998) - et al.
Economic and life consequences experienced by a group of individuals with panic disorder
Journal of Anxiety Disorders
(1990)
Cost of anxiety disorders: impact of comorbidity
Journal of Psychosomatic Research
Affordable care act
Cost of disorders of the brain in Europe
European Journal of Neurology
Cost of anxiety disorders in Europe
European Journal of Neurology
Incremental healthcare utilization and expenditures for allergic rhinitis in the United States
Laryngoscope
CPI detailed report data for March, 2013
Economic costs of anxiety disorders
Anxiety
The health and productivity cost burden of the top 10 physical and mental health conditions affecting six large U.S. employers in 1999
Journal of Occupational and Environmental Medicine
The economic burden of anxiety disorders in the 1990
Journal of Clinical Psychiatry
Considerations in the treatment of anxiety disorders: a pharmacoeconomic review
Expert Opinion on Pharmacotherapy
Cited by (35)
Flexible piezo-electrocatalytic uric acid sensor
2023, Nano EnergyHealth impacts of bike-sharing systems in the U.S.
2021, Environmental ResearchCitation Excerpt :Direct and indirect health costs for dementia, breast cancer, colon cancer, ischemic heart disease, stroke, and type 2 diabetes were obtained from a recent report from the U.S. (Waters and Marlon, 2018). Direct and indirect health costs for anxiety (Johnston et al., 2009; Shirneshan et al., 2013), depression (Chow et al., 2019), lung cancer (Pisu et al., 2018; Singleterry, 2017), and Parkinson's disease (Yang et al., 2020b) in the U.S. were collected from scientific publications. The Centers for Disease Control and Prevention Web-based Injury Statistics Query and Reporting System (WISQARS) database was utilized to assess the costs associated with traffic injuries (“Cost of Injury & Calculators | WISQARS | Injury Center | CDC,” 2020).
Incremental Economic Burden of Depression in Ophthalmic Patients
2021, American Journal of OphthalmologyCitation Excerpt :While there are limited studies available, Lee and associates31 reported in a prospective pilot survey study with 50 consecutive ophthalmology clinic outpatient visits at the University of Iowa that it was possible to screen for depression in elderly patients with minimal inefficiencies. The total economic burden of depression in the United States has risen to an estimated $210.5 billion.32,33 This study reports an additional $22.4 billion in annual direct incremental expenditures to the U.S. health care system as part of health care for ophthalmic patients with depression.
Deep learning paired with wearable passive sensing data predicts deterioration in anxiety disorder symptoms across 17–18 years
2021, Journal of Affective DisordersCognitive Behavioral Therapy for Anxiety Disorders: Outcomes From a Multi-State, Multi-Site Primary Care Practice
2021, Journal of Anxiety DisordersAnxiety Disorders in Primary Care Settings
2019, Nursing Clinics of North AmericaCitation Excerpt :Psychometric tools assist the provider in diagnosing, treating, and assessing changes in anxiety levels following treatment response; however, it is pertinent to ensure that the patient’s subjective response is also considered when evaluating changes in symptoms severity. Treatment decisions should thus be dictated by patient choice and subjective experience.4 For an overview of free adult psychometric scales for anxiety see Table 3.
- 1
Now at School of Pharmacy, Chapman University, United States.